Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,000.00 Price Target at Oppenheimer

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price reduced by Oppenheimer from $1,150.00 to $1,000.00 in a report released on Wednesday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock.

REGN has been the subject of a number of other research reports. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday. Leerink Partnrs cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Finally, BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,092.62.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $816.65 on Wednesday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 52 week low of $783.57 and a 52 week high of $1,211.20. The company has a market cap of $90.03 billion, a PE ratio of 20.21, a P/E/G ratio of 3.17 and a beta of 0.15. The business has a 50 day moving average of $1,035.92 and a 200 day moving average of $1,038.36.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.48% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock valued at $8,595,268,000 after buying an additional 91,956 shares during the period. Capital International Investors boosted its position in Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after purchasing an additional 213,038 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after purchasing an additional 184,561 shares during the last quarter. International Assets Investment Management LLC increased its holdings in Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in Regeneron Pharmaceuticals by 12.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock worth $567,864,000 after acquiring an additional 59,769 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.